The post SpaceX IPO’s hot trade: NASA ETF’s two-month, $2.6 billion liftoff appeared on BitcoinEthereumNews.com. Retail investors are rushing into the space investingThe post SpaceX IPO’s hot trade: NASA ETF’s two-month, $2.6 billion liftoff appeared on BitcoinEthereumNews.com. Retail investors are rushing into the space investing

SpaceX IPO’s hot trade: NASA ETF’s two-month, $2.6 billion liftoff

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Retail investors are rushing into the space investing trade ahead of the SpaceX IPO, and one ETF has cashed in on the excitement.

Tema ETFs’ Space Innovators ETF, which launched on March 30 and trades under the ticker symbol NASA, crossed $1 billion in assets in just 37 trading days, and by the end of this past trading week, had reached over $2.6 billion in assets.

That rapid rise is due in part to retail investors hunting for exposure to SpaceX before it goes public.

While SpaceX has taken an unusual approach to its offering, setting up access for retail investors through brokerage firms at a level atypical in new deals typically dominated by institutions, the NASA fund is another alternative for investors to gain access to Elon Musk’s rocket company. It already holds privately traded SpaceX shares directly. It is one of the few investment vehicles available to retail investors that does, with SpaceX currently representing around 7.5% of the fund.

“If we’re going to invest in space … We have to offer exposure to SpaceX,” said Maurits Pot, Tema ETFs founder and CEO on CNBC’s “ETF Edge” on Wednesday.

Pot said there is no plan to sell shares once the IPO occurs. “The IPO for us is simply a remarking of the position to market price,” he said.

Stock chart icon

NASA 1 M

NASA isn’t the only ETF that has access to SpaceX, though the options are limited. Mutual fund manager and billionaire Ron Baron, a long-time Tesla and SpaceX investor, owns the rocket company through his First Principles fund (RONB). Tesla is the top holding in the RONB ETF, at over 14%, while holding close to 2% of the fund’s assets in SpaceX. The ERShares Private-Public Crossover ETF (XOVR), which offers access to late-stage private companies, also owns shares of SpaceX, which it says are worth close to $300 million based on an expected IPO value of over $1.5 trillion.

Setting a precise valuation for the SpaceX deal remains a point of contention in the market and among investors ahead of the deal’s pricing.

Mike Akins, founding partner at ETF Action, said on “ETF Edge” that the ETF structure itself is what makes this kind of access possible for the everyday investor. “Ten, twenty years ago, you talked about a space theme like this, an investor would have to go out and look up all these companies. Now there’s a ticker,” Akins said.

Todd Sohn, chief ETF strategist at Strategas, noted that several new space ETFs have launched over the past few months, including the Van Eck Space ETF (WARP), the Global X Space Tech ETF (ORBX), and Roundhill Investments’ Space & Technology ETF (MARS), which is itself a signal that retail investors are expected to pursue the theme as they have with other recent thematic trades playing off tech innovation, from AI to quantum computing. “That to me is usually a pretty good read that the industry expects space to be the next big thing,” Sohn told CNBC. “It’s a very similar idea to what AI was a few years ago and continuing on.”

But Sohn cautioned that not all funds are created equal. “It all depends on how pure or watered down the ETF is. So the due diligence for this is really important now,” he said.

There are other ETFs branded under the space investing theme that have been in the market for years already, building portfolios of stocks that include pure-play, high-risk space exploration companies, satellite companies, and broader aerospace and defense sector names.

The Procure Space ETF (UFO), which launched in 2019 and has over $1.2 billion in assets, holds Rocket Lab, Firefly Aerospace, and Planet Labs among its top holdings. The SPDR S&P Kensho Final Frontiers ETF (ROKT), which launched in 2018, also holds Intuitive Machines and Redwire.

Stock chart icon

Five-year performance of UFO ETF which invests in space and aerospace stocks.

The ARK Space and Defense Innovation ETF (ARKX) is a good example of how the definitional set of top stocks can range far across the market, with its portfolio also including Amazon and Deere.

Sohn says investors interested in these ETFs and the space investing theme should consider how much overlap there is in a portfolio with more classic defense industry names, as well as how concentrated the fund is in a small group of high-risk stocks.

“There’s only so many companies who are doing this that are public,” Sohn said. “Some of them may have 30 holdings, some of them may have closer to 50 or so,” he said of the current crop of space ETFs. “I have a feeling once SpaceX is public and trading for some time, you’re going to see some of these funds morph into more concentrated bets, depending on how they are managed,” he said.

That’s another factor for investors to consider: NASA, for example, is an actively managed fund, rather than tracking an existing index of stocks designed to represent the theme, which is the approach of UFO, ORBX, ROKT and others.

Investors will pay more for an actively managed approach from a stock picker in space: NASA has an annual net expense ratio of 0.87%, while ORBX charges 0.50%, and ROKT’s expense ratio is 0.45%.

It is clear that Elon Musk is going to be a big winner from the SpaceX IPO and likely the world’s first trillionaire. But both Akins and Sohn said the biggest risk for retail investors getting in on the space theme is volatility.

The risks in the space market were made vivid this week with the launchpad explosion of Blue Origin’s New Glenn rocket.

“Expect volatility. That is usually what happens with very early-stage industries. There will be companies that outperform and companies within ETFs that fall apart because the business model doesn’t make sense,” Sohn said.

Sign up for our weekly newsletter that goes beyond the livestream, offering a closer look at the trends and figures shaping the ETF market.

Disclaimer

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Source: https://www.cnbc.com/2026/05/30/spacex-ipo-invest.html

Market Opportunity
Polytrade Logo
Polytrade Price(TRADE)
$0.03906
$0.03906$0.03906
+0.48%
USD
Polytrade (TRADE) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage